Janoshik Analytical: difference between revisions
Diff·revision 16 → 17·19:35, 15 Apr 2025
Difference between revision 16 and revision 17 of Janoshik Analytical. 12 lines changed; the page grew by 843 bytes.
| Revision 16 — 22:54, 19 Mar 2025 COA_Colwyn (talk) add the second-opinion point: two services, one lot, is a stronger record 4,126 bytes ±0 | Revision 17 — 19:35, 15 Apr 2025 LeanMassLars (talk) add the difference between a batch certificate and a lot-specific one 4,969 bytes +843 | ||
|---|---|---|---|
| 29 | Where a submitted report and a supplier's [[Certificate of analysis|certificate]] cover the same lot, agreement between them establishes that two measurements agreed. It does not establish that the sample represented the lot, and it is not a substitute for [[Blind sampling|blind sampling]] with a documented [[Chain of custody|chain of custody]].{{r|usp1503}} | 29 | Where a submitted report and a supplier's [[Certificate of analysis|certificate]] cover the same lot, agreement between them establishes that two measurements agreed. It does not establish that the sample represented the lot, and it is not a substitute for [[Blind sampling|blind sampling]] with a documented [[Chain of custody|chain of custody]].{{r|usp1503}} |
| 30 | 30 | ||
| + | 31 | == Interpreting a chromatogram == | |
| + | 32 | A reader without chromatographic training can still extract useful information from a released trace, and the article on [[Reverse-phase HPLC]] covers the mechanics. Three observations are accessible without specialist knowledge. | |
| + | 33 | ||
| + | 34 | |+ Features visible on a released trace, and what each may indicate{{r|usp621}} | |
| + | 35 | | Feature | What it suggests | | |
| + | 36 | |---|---| | |
| + | 37 | | Baseline drift | Gradient or column condition; large drift makes integration uncertain | | |
| + | 38 | | Peak asymmetry | Overload, secondary interactions, or a co-eluting species | | |
| + | 39 | | Very short run time | Little opportunity to separate close-eluting impurities | | |
| + | 40 | | Integration extending well past peak return to baseline | Purity figure may include unresolved material | | |
| + | 41 | ||
| 31 | == References == | 42 | == References == |
| 32 | {{reflist}} | 43 | {{reflist}} |
| ⋮ | ⋮ | ||
| 34 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref> | 45 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref> |
| 35 | <ref name="iso17025">ISO/IEC 17025:2017, ''General requirements for the competence of testing and calibration laboratories''.</ref> | 46 | <ref name="iso17025">ISO/IEC 17025:2017, ''General requirements for the competence of testing and calibration laboratories''.</ref> |
| + | 47 | <ref name="usp621">United States Pharmacopeia, General Chapter <621>, ''Chromatography''.</ref> | |
| 36 | 48 | ||
| 37 | == See also == | 49 | == See also == |